Financial updates
Pharming Announces Financing Plans for Closing of RUCONEST® North American Rights Acquisition
Pharming Group N.V. announces its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016.
“I am absolutely delighted to be able to confirm that, subject to final documentation, we have secured good terms on new financing instruments with first class investors looking to support Pharming over the long term in its new growth phase."
- Sijmen de Vries - CEO